close
Public Relations
REYON, A Company That Communicates Openly and Transparently
REYON News
Total 61
Reyon Pharmaceutical’s Partner Elisigen Wins Bayer Co.Lab Connect Seoul… Global Competence in Gene Therapy Proven
2026.10.15
Reyon Pharmaceutical’s Partner Elisigen Demonstrates ‘Visual Improvement’ and Announces Consistent Efficacy Results of NG101 in High-Dose Group at AAO, the World's Largest Ophthalmology Congress
2026.10.13
T&R Biofab Acquires Stake in Reyon Pharmaceutical… “Beyond Joint Development to a Hemostatic Agent Alliance”
2026.09.28
Reyon Pharmaceutical Accelerates Global Expansion of Thrombin... Full-scale Establishment in Overseas Markets
2026.09.07
Reyon Pharmaceutical and Elisigen Jointly Present Successful Mid-Dose Clinical Data for 'NG101' at ASRS… Confirming Superior Low-Dose, High-Efficacy and Commercial Viability Over Competitors
2026.07.20
Reyon Pharmaceutical’s Partner Elisigen to Deliver Oral Presentation on ‘NG101’ at ASRS 2026… “Standing Shoulder-to-Shoulder with Global Big Pharma”
2026.07.14
Japanese Biotech Companies to Make Consecutive Visits to Reyon Pharmaceutical's Manufacturing Plant in July
2026.06.15
Reyon Pharmaceutical Adds New Cash Cow, Launching Full-Scale Entry into the 300 Billion KRW Hemostatic Agent Market
2026.06.09
Reyon Pharmaceutical: "Chemical Earning Power + Novel Drug Growth Potential… The Inaugural Year of Our Biopharmaceutical Leap"
2026.05.27
High Expectations for NG101 as a Global Novel Drug, While Chemical Segment Defends Profitability
2026.05.18